Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03RRJ
|
|||
| Former ID |
DNC000803
|
|||
| Drug Name |
Iodine-131-tositumomab
|
|||
| Drug Type |
Antibody
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | . | [1], [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008 Aug 1;112(3):830-5. | |||
| REF 2 | A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000 Nov 1;96(9):2934-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.